摘要
在工业化国家中风是最常见发病率和死亡率的神经系统病例,每年困扰1500万人。这些数字预计将增加,主要是由于人口老龄化。五分之一中风患者死亡,三分之一为永久性残疾。 虽然一些急性期治疗如静脉重组组织型纤溶酶原激活物(rt-PA)和介入治疗已被证明可以改善缺血性中风的结果,但是这些方法只对一小部分患者可用。 使用干细胞代替在中风中时失去的脑细胞是一个长期的目标,考虑到移植的细胞必须整合和恢复神经通路恢复受损部位的功能,它是难以实现的。在过去的十年中,使用间充质干细胞(MSCs)作为治疗已经成为一个特别有吸引力的选择。 间充质干细胞是一类多能干细胞,产生分化后代当植入适当的组织的自我更新细胞。在这里,我们提出了一个骨髓间充质干细胞在缺血性中风的应用的总结,包括骨髓间充质干细胞的来源,其传递到大脑和终点测量的路线和时间。在动物脑卒中模型中移植骨髓间充质干细胞的实验数据表明一种改进的功能恢复。骨髓间充质干细胞的移植通过调节炎症环境影响了广泛的活动,刺激内源性神经发生和血管生成和减少胶质瘢痕的形成,尽管确切的这种现象的基本机制仍不清楚。从早期的临床试验的结果突出优化变量的需要,如为了将这些结果转化为安全和成功的临床应用进行细胞选择和路线管理。
关键词: 缺血性中风,人脂肪间充质干细胞,细胞治疗。
Current Medicinal Chemistry
Title:Mesenchymal Stem Cells for Ischemic Stroke: Progress and Possibilities
Volume: 23 Issue: 16
Author(s): Anna Lucia Maria Ferri, Anna Bersano, Daniela Lisini, Giorgio Boncoraglio, Simona Frigerio, Eugenio Parati
Affiliation:
关键词: 缺血性中风,人脂肪间充质干细胞,细胞治疗。
摘要: Stroke is the most common neurological cause of morbidity and mortality in industrialized countries, afflicting 15 million people every year. The numbers are expected to increase, mostly due to aging populations. One in five stroke patients dies, and one in three are left with permanent disabilities.
Although some acute phase therapies such as intravenous recombinant tissue plasminogen activator (rt-PA) andendovascular treatment have been shown to improve ischemic stroke outcome, these therapies are available only for a small proportion of patients.
The use of stem cells to replace brain cells lost during stroke is a long-term goal, and one which is difficult to achieve given that transplanted cells must integrate and restore neural pathways to regain function of damaged parts of the brain. Over the past decade the use of mesenchymal stromal cells (MSCs) as therapy has emerged as a particularly attractive option.
MSCs are a class of multipotent, self-renewing cells that give rise to differentiated progeny when implanted into appropriate tissues. Herein, we present a review of the application of MSCs in ischemic stroke, including the source of MSCs, the route and timing of their delivery into the brain and the endpoints measured. Experimental data of transplantation of MSCs in animal stroke models suggest an improved functional recovery. The transplantation of MSCs influences a wide range of events by modulating the inflammatory environment, stimulating endogenous neurogenesis and angiogenesis and reducing the formation of glial scar, although the precise, underlying mechanism of this phenomenon remains unknown. The results from early clinical trials highlight the need to optimize variables such as cell selection and route of administration in order to translate these results into safe and successful clinical applications.
Export Options
About this article
Cite this article as:
Anna Lucia Maria Ferri, Anna Bersano, Daniela Lisini, Giorgio Boncoraglio, Simona Frigerio, Eugenio Parati , Mesenchymal Stem Cells for Ischemic Stroke: Progress and Possibilities, Current Medicinal Chemistry 2016; 23 (16) . https://dx.doi.org/10.2174/0929867323666160222113702
DOI https://dx.doi.org/10.2174/0929867323666160222113702 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Hierarchical Profiles of Signaling Pathways and Networks Reveal Two Complementary Pharmacological Mechanisms
CNS & Neurological Disorders - Drug Targets Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design Biology of Heme in Health and Disease
Current Medicinal Chemistry Albumin Induces Neuroprotection Against Ischemic Stroke by Altering Toll-Like Receptor 4 and Regulatory T Cells in Mice
CNS & Neurological Disorders - Drug Targets Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets COXIBs, CINODs and H2S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Current Signal Transduction Therapy Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Human Heart Failure: A Proteomics Perspective
Current Proteomics Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Alkannins and Shikonins: A New Class of Wound Healing Agents
Current Medicinal Chemistry